Importance Obesity affects approximately 42% of US adults and is associated with increased
rates of type 2 diabetes, hypertension, cardiovascular disease, sleep disorders …

We summarized and compared meta-analyses of pharmacological and non-
pharmacological interventions targeting physical health outcomes among people with …

Antipsychotic medications are critical to child and adolescent psychiatry, from the
stabilization of psychotic disorders like schizophrenia, bipolar disorder, and psychotic …

Psychotropic drug–related weight gain (PDWG) is a common occurrence and is highly
associated with non-initiation, discontinuation, and dissatisfaction with psychiatric drugs …

Metabolic disturbances and obesity are major cardiovascular risk factors in patients with
schizophrenia, resulting in a higher mortality rate and shorter life expectancy compared with …

Background Atypical antipsychotics, also known as second-generation antipsychotics, are
commonly prescribed as treatment for psychotic disorders in adults, as well as in children …

Aim In this review, the author focused on anticraving therapy for alcohol use disorder (AUD)
defined by DMS‐5. A comprehensive review was carried out on the available published …

Introduction: Patients living with schizophrenia have a marked risk of clinically significant
weight gain and obesity compared to the general population. The risks have been …

Metformin is the currently accepted first-line treatment for antipsychotic-associated weight
gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 …

Background: There have been a few systematic reviews and conventional meta-analyses
reporting effect of drugs on metabolic disturbance induced by atypical antipsychotics (AAPs) …